Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424792 | 1.00 | MDM2 (0.46) | MDM2CASP3CA1CA2TLR2 | |
| SCHEMBL30731420 | 1.00 | MDM2 (0.46) | MDM2CASP3CA1CA2TLR2 | |
| SCHEMBL29423558 | 1.00 | MDM2 (0.46) | MDM2CASP3CA1CA2TLR2 | |
| SCHEMBL22690415 | 1.00 | MDM2 (0.46) | MDM2CASP3CA1CA2TLR2 | |
| SCHEMBL31727174 | 0.98 | MDM2 (0.45) | MDM2CASP3CA1CA2TLR2 | |
| SCHEMBL17550375 | 0.93 | MDM2 (0.44) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL13401516 | 0.93 | MDM2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL16325412 | 0.93 | MDM2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL31726487 | 0.91 | MDM2 (0.43) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL31727026 | 0.91 | MDM2 (0.43) | MDM2CASP3CA1CA2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| CN-117136076-A | MCL-1 inhibitor antibody drug conjugates and methods of use | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | MDM2 528/4885CASP3 597/4885CA1 3686/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | MDM2 533/4885CASP3 809/4885CA1 2220/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | MDM2 1619/4885CASP3 321/4885CA1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.